Compare IDEXX Laboratories, Inc. (IDXX) vs MACOM Technology (MTSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MACOM Technology — how do they compare? IDEXX Laboratories, Inc. trades at $543.15 (market cap $41.68B), while MACOM Technology trades at $270.23 (market cap $22.25B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and MACOM Technology is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and MACOM Technology for 8 Days on average.
| IDXX | MTSI | |
|---|---|---|
Market Cap | $41.68B | $22.25B |
Volume | 824,427 | 1,772,525 |
Sector | Health | Technology |
52-Week High | $766.68 | $409.68 |
52-Week Low | $504.70 | $135.91 |
Typical Hold Time | 47 Days | 8 Days |
Enterprise Value | $42.58B | $21.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $540.5, up 3.88% in the last 24 hours, with a neutral technical signal and key resistance at $538. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $4.3B in 2025, and profitability remains robust with a 25.03% net income margin. Recent acquisitions, such as CoVetAI, aim to enhance veterinary workflow intelligence, supporting long-term growth targets.
The outlook for IDXX is positive, driven by consistent earnings outperformance and strategic expansions. However, risks include foreign exchange volatility and softer U.S. veterinary visits. Analyst consensus is bullish with a $665 price target, suggesting ~23% upside from current levels, but investors should monitor competitive pressures and macroeconomic headwinds.
MACOM Technology Solutions (MTSI) trades at $308.75, up 0.78% with strong momentum driven by AI semiconductor demand. The stock shows bullish technical signals with recent earnings beats and analyst consensus pointing to 35% upside potential. Revenue growth accelerated from $967M in 2025 to $1.2B in 2026 while achieving profitability turnaround from -$54M to $241M net income. Recent product launches in optical connectivity and institutional accumulation support the positive momentum.
Outlook remains favorable with semiconductor industry tailwinds and AI-driven demand, though elevated valuation multiples (P/E 98.33) and competitive pressures present risks. The consensus price target of $415.71 suggests significant upside if execution continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MACOM Technology
MACOM develops analog, radio frequency, microwave, and optical semiconductors. Its components are used in telecommunications, data centers, industrial systems, aerospace, and defense applications.
Read more on MTSI →
